Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.

Abstract

BACKGROUND:

Lenalidomide has demonstrated remarkable efficacy for therapy of lower-risk myelodysplastic syndromes (MDS) associated with 5q(-). The present evaluation aimed to describe the characteristics and outcomes of low-risk MDS patients treated with lenalidomide in Austria.

PATIENTS AND METHODS:

For this retrospective, multicenter, observational analysis of MDS patients who received lenalidomide, data were collected at various hospitals in Austria over a period of 3 years. MDS classification, previous and current MDS therapies, and outcome and safety of lenalidomide were evaluated.

RESULTS:

Forty-six percent of the patients (n = 23) had a 5q(-) syndrome, while 12% (n = 6) exhibited 5q(-) plus additional aberrations or isolated 5q(-) but ≥ 5% blasts in the bone marrow (10%, n = 5). The remaining 32% of patients (n = 16) had MDS with other World Health Organization classifications. Seventy percent belonged to lower International Prognostic Scoring System risk classes. Sixteen centers participated, involving a total of 50 patients. Most frequently used lenalidomide doses were 10 mg and 5 mg on days 1 to 21 of a 28-day cycle. Seventy-five percent of the patients received 11 months of treatment, with a median therapy period of 3.5 months; median follow-up was 3.9 months (range, 0-26 months). Response rate, defined as transfusion independence during the 2 months after lenalidomide therapy, was 64%. Median overall survival was not reached.

CONCLUSION:

Lenalidomide was well tolerated and is an effective and well-tolerated option for therapy of patients with 5q(-) syndrome but also lower-risk MDS patients with other World Health Organization classifications in clinical practice.

• Authors: Gregor Aschauer, Richard Greil, Werner Linkesch, Thomas Nösslinger, Richard Stauder, Sonja Burgstaller, Michael Fiegl, Michael Fridrik, Michael Girschikofsky, Felix Keil, Andreas Petzer
• Journal: Clinical lymphoma, myeloma & leukemia (Clin Lymphoma Myeloma Leuk) Vol. 15 Issue 11 Pg. e143-9 (Nov 2015) ISSN: 2152-2669 [Electronic] United States
• PMID: 26422252 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Immunologic Factors
• Thalidomide
• Lenalidomide

Topics

• Adult
• Aged
• Aged, 80 and over
• Anemia, Macrocytic (genetics)
• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Austria
• Chromosome Aberrations
• Chromosome Deletion
• Chromosomes, Human, Pair 5 (genetics)
• Comorbidity
• Disease Progression
• Erythrocyte Transfusion
• Female
• Humans
• Immunologic Factors (administration & dosage, therapeutic use)
• Lenalidomide
• Male
• Middle Aged
• Myelodysplastic Syndromes (drug therapy, genetics, mortality, pathology)
• Retrospective Studies
• Standard of Care
• Survival Analysis
• Thalidomide (administration & dosage, analogs & derivatives, therapeutic use)
• Treatment Outcome